Fate Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-190.05	-160.93	-281.72	-212.15	-173.39	-98.15	Upgrade
Depreciation & Amortization	18.91	18.28	13.76	5.85	3.09	2.19	Upgrade
Share-Based Compensation	43.46	43.46	78.73	54.36	30.75	17.41	Upgrade
Other Operating Activities	-9.07	-33.08	-58.98	-10.93	100.32	-4.63	Upgrade
Operating Cash Flow	-136.75	-132.26	-248.21	-162.87	-39.23	-83.18	Upgrade
Capital Expenditures	-3.03	-6.15	-35.57	-50.7	-4.93	-7.4	Upgrade
Change in Investments	123.67	118.82	202.32	-273.32	-156.14	-150.06	Upgrade
Investing Cash Flow	120.64	112.67	166.75	-324.02	-161.08	-157.45	Upgrade
Share Issuance / Repurchase	75.37	0.09	9.21	432.45	282.35	164.93	Upgrade
Debt Issued / Paid	0	0	0	0	0	-15	Upgrade
Other Financing Activities	20	-	-	20.68	0.49	-	Upgrade
Financing Cash Flow	95.37	0.09	9.21	453.13	282.84	149.93	Upgrade
Net Cash Flow	79.25	-19.51	-72.25	-33.76	82.53	-90.7	Upgrade
Free Cash Flow	-139.78	-138.42	-283.77	-213.57	-44.16	-90.57	Upgrade
Free Cash Flow Margin	-2157.83%	-217.86%	-294.68%	-382.43%	-140.49%	-848.03%	Upgrade
Free Cash Flow Per Share	-1.38	-1.41	-2.93	-2.25	-0.54	-1.33	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).